Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genor Biopharma Holdings Limited ( (HK:6998) ) has issued an update.
Edding Genor Group Holdings Limited has completed a very substantial acquisition via a merger between its merger subsidiary and the target company, with the transaction structured as a reverse takeover and satisfied through the issue of approximately 1.48 billion consideration shares under a specific mandate. The merger’s effective completion on 30 December 2025 follows shareholder approval and listing consent for the new shares, and is accompanied by a broad corporate overhaul including a new company name, logo and website, adoption of a one-off share option plan, removal of the stock marker, and changes to the board, board committees, authorised representatives, joint company secretaries and principal place of business in Hong Kong, signalling a significant repositioning of the group’s capital structure and governance for its next phase of development.
More about Genor Biopharma Holdings Limited
Edding Genor Group Holdings Limited, formerly known as Genor Biopharma Holdings Limited, is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange. The group operates in the biopharmaceutical sector, focusing on the development and commercialisation of innovative therapies, with its shares traded under stock code 6998 on the Main Board.
YTD Price Performance: 76.30%
Average Trading Volume: 813,079
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.61B
Find detailed analytics on 6998 stock on TipRanks’ Stock Analysis page.